Ginsenoside Suppresses Triple-Negative Breast Cancer Growth and Synergizes With Programmed Cell Death Protein 1 (PD-1) Immunotherapy Through Gut Microbiota and Metabolic Regulation
{{output}}
Breast cancer accounts for 30% of all malignancies and ranks second in cancer-related mortality. Triple-negative breast cancer (TNBC) lacks estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 (HER2) and presents unique therap... ...
